{ "schema_version": "LEDGER-SCHEMA-1.0", "session_date": "2026-07-09", "sealed_at": "2026-07-10T13:29:16-04:00", "regime": "risk_on", "rows": [ { "ticker": "ALNY", "side": "LONG", "catalyst_type": "clinical_data", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "Amvuttra ATTR-CM franchise share/peak sales", "catalyst_score": 95, "tradeability": null, "trr_modifier": 1.15, "structural_anchor": null, "ces": 59.9, "tier": "Quality", "invalidation": null, "position_disclosure": "none", "kvd_note": "Competitor eplontersen (AZ/Ionis) CARDIO-TTRansform Ph3 missed primary endpoint (no effect on stabilizer background); Amvuttra left as sole outcomes-proven TTR silencer in ATTR-CM." }, { "ticker": "SMPL", "side": "LONG", "catalyst_type": "earnings_beat", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "organic net-sales trajectory + gross margin", "catalyst_score": 80, "tradeability": null, "trr_modifier": 0.85, "structural_anchor": null, "ces": 34.9, "tier": "Marginal", "invalidation": null, "position_disclosure": "none" }, { "ticker": "VRAX", "side": "LONG", "catalyst_type": "contract_win", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "commercial supply agreements / first revenue", "catalyst_score": 65, "tradeability": null, "trr_modifier": 0.85, "structural_anchor": null, "ces": 34.9, "tier": "Marginal", "invalidation": null, "position_disclosure": "none" }, { "ticker": "BBIO", "side": "LONG", "catalyst_type": "clinical_data", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "Attruby ATTR-CM script ramp / stabilizer SOC position", "catalyst_score": 80, "tradeability": null, "trr_modifier": 1.05, "structural_anchor": null, "ces": 33.3, "tier": "Marginal", "invalidation": null, "position_disclosure": "none" }, { "ticker": "AZZ", "side": "LONG", "catalyst_type": "guidance_raise", "catalyst_timestamp": "2026-07-08", "catalyst_age_sessions": 1, "kvd": "FY27 forward revenue/EBITDA guide + Metal Coatings volume", "catalyst_score": 87.5, "tradeability": null, "trr_modifier": 1.15, "structural_anchor": null, "ces": 17.9, "tier": "Marginal", "invalidation": null, "position_disclosure": "none" }, { "ticker": "AP", "side": "LONG", "catalyst_type": "contract_win", "catalyst_timestamp": "2026-07-08", "catalyst_age_sessions": 1, "kvd": "committed-demand / order backlog", "catalyst_score": 80, "tradeability": null, "trr_modifier": 0.95, "structural_anchor": null, "ces": 14.6, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "RKTO", "side": "LONG", "catalyst_type": "other", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "narrative / AI association - no measurable KVD", "catalyst_score": 65, "tradeability": null, "trr_modifier": 0.85, "structural_anchor": null, "ces": 14.6, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "RPGL", "side": "LONG", "catalyst_type": "other", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "listing-status overhang (not a business KVD)", "catalyst_score": 65, "tradeability": null, "trr_modifier": 0.85, "structural_anchor": null, "ces": 12.3, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "FCEL", "side": "LONG", "catalyst_type": "partnership", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "committed demand / platform economics", "catalyst_score": 65, "tradeability": null, "trr_modifier": 0.85, "structural_anchor": null, "ces": 10.3, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "ENVX", "side": "LONG", "catalyst_type": "other", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "manufacturing yield / scale-up execution", "catalyst_score": 65, "tradeability": null, "trr_modifier": 0.85, "structural_anchor": null, "ces": 8.6, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "AMAT", "side": "LONG", "catalyst_type": "analyst_initiation", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "WFE capex cycle / leading-edge intensity", "catalyst_score": 65, "tradeability": null, "trr_modifier": 0.9, "structural_anchor": null, "ces": 8.4, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "GLSI", "side": "LONG", "catalyst_type": "regulatory", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "FLAMINGO-01 Phase III readout (unchanged)", "catalyst_score": 65, "tradeability": null, "trr_modifier": 0.85, "structural_anchor": null, "ces": 8.3, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "SUNE", "side": "LONG", "catalyst_type": "other", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "ownership/flow disclosure (not a business KVD)", "catalyst_score": 65, "tradeability": null, "trr_modifier": 0.85, "structural_anchor": null, "ces": 5.5, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "MU", "side": "LONG", "catalyst_type": "other", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "AI/HBM memory pricing & forward bookings", "catalyst_score": 65, "tradeability": null, "trr_modifier": 0.9, "structural_anchor": null, "ces": 3.6, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "IONS", "side": "SHORT", "catalyst_type": "regulatory_rejection", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "eplontersen ATTR-CM expansion opportunity", "catalyst_score": 87.5, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 59.9, "tier": "Quality", "invalidation": null, "position_disclosure": "none", "kvd_note": "7/9 pre-mkt: CARDIO-TTRansform Ph3 of eplontersen (Wainua) in ATTR-CM MISSED the primary composite endpoint (CV mortality + recurrent CV events to Wk140). Pre-specified monotherapy subgroup nominally significant HR 0.71; safety favorable; full data at ESC Aug-2026." }, { "ticker": "AZN", "side": "SHORT", "catalyst_type": "regulatory_rejection", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "Wainua ATTR-CM franchise option value", "catalyst_score": 87.5, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 47, "tier": "Quality", "invalidation": null, "position_disclosure": "none", "kvd_note": "7/9 pre-mkt: partner Ionis + AZ announce CARDIO-TTRansform Ph3 (Wainua/eplontersen, ATTR-CM) missed primary endpoint. ATTR-CM was AZs largest cardiometabolic expansion option; ALNY +15% pre-mkt on the read-across." }, { "ticker": "BYRN", "side": "SHORT", "catalyst_type": "earnings_miss", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "e-commerce conversion + dealer/chain reorder revenue", "catalyst_score": 85, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 22.5, "tier": "Marginal", "invalidation": null, "position_disclosure": "none" }, { "ticker": "RXT", "side": "SHORT", "catalyst_type": "guidance_cut", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "FY26 revenue/EBITDA guide + capital structure", "catalyst_score": 100, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 16.3, "tier": "Marginal", "invalidation": null, "position_disclosure": "none" }, { "ticker": "MDA", "side": "SHORT", "catalyst_type": "offering_dilution", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "share count / capital structure (structural KVD)", "catalyst_score": 80, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 13.5, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "PEP", "side": "SHORT", "catalyst_type": "kpi_deterioration", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "PFNA (Frito-Lay NA) organic revenue & volumes", "catalyst_score": 85, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 12.9, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "IBM", "side": "SHORT", "catalyst_type": "analyst_downgrade", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "software+consulting AI-disintermediation risk (no measured delta)", "catalyst_score": 77.5, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 10.5, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "META", "side": "SHORT", "catalyst_type": "margin_compression", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "capex intensity & FCF trajectory", "catalyst_score": 82.5, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 10.1, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "LEVI", "side": "SHORT", "catalyst_type": "earnings_miss", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "Levis brand organic growth + gross margin - INTACT/ACCELERATING", "catalyst_score": 77.5, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 8.8, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "TRNR", "side": "SHORT", "catalyst_type": "offering_dilution", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "share count / going concern (structural KVD, NO dated anchor)", "catalyst_score": 77.5, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 5.7, "tier": "Pass", "invalidation": null, "position_disclosure": "none" }, { "ticker": "PLTR", "side": "SHORT", "catalyst_type": "analyst_downgrade", "catalyst_timestamp": "2026-07-09", "catalyst_age_sessions": 0, "kvd": "US commercial growth / NDR - INTACT", "catalyst_score": 72.5, "tradeability": null, "trr_modifier": null, "structural_anchor": null, "ces": 5.3, "tier": "Pass", "invalidation": null, "position_disclosure": "none" } ] }